echemi logo
Product
  • Product
  • Supplier
  • Inquiry
    Home > Active Ingredient News > Drugs Articles > API industry faces upgrading and intensive production level to be improved

    API industry faces upgrading and intensive production level to be improved

    • Last Update: 2019-04-01
    • Source: Internet
    • Author: User
    Search more information of high quality chemicals, good prices and reliable suppliers, visit www.echemi.com
    [market analysis of chinapharma.com] in recent years, a number of large-scale price increases have taken place in some domestic APIs, which has a certain impact on the benefits of some downstream pharmaceutical enterprises For example, due to the rising price of raw materials and the small number of drug manufacturers, the price of domestic nitroglycerin "small brown bottle" of 6 yuan and 100 tablets rose to 69 yuan / bottle on the e-commerce platform On the contrary, in this context, pharmaceutical enterprises with their own API production capacity can ensure the normal supply of pharmaceutical raw materials in short supply, so as to cope with the situation of short supply in the market For example, due to the impact of large-scale price increase of APIs, Asia Pacific pharmaceutical industry has chosen its own core generic drugs to study its API process and produce in its own API plant For the rest of the products, strategic cooperation with API manufacturers will be carried out to ensure that they will not be passive for a period of time For innovative drugs, Apis themselves are produced by enterprises themselves, so as to ensure a more stable supply of products Industry insiders believe that if enterprises can produce their own APIs, it is also conducive to solve the problem of API monopoly "We should promote the reform of the approval system of APIs as soon as possible If large pharmaceutical enterprises can produce APIs themselves and the number of API enterprises becomes larger, there will be no monopoly." At present, many enterprises with environmental protection strength are making strategic transformation from API to preparation, adopting the strategy of "two wheel drive of API and preparation", accelerating preparation production and expanding export channels on the premise of continuous production of API For example, TIANYAO Pharmaceutical Co., Ltd and its subsidiary Jinyao Pharmaceutical Co., Ltd have realized the substantial business integration of API production and preparation production, connected the upstream and downstream industrial chains, and formed a two-wheel linkage development model of raw materials and preparation products The performance driving force is more significant, and the company is expected to usher in greater development in the next few years It is worth noting that preparations are in a connecting position in the pharmaceutical industry chain, and play an important role in supporting the research and development of new drugs and promoting the industrialization of new drugs Therefore, the transformation from APIs to preparations needs to consider the strength of enterprises, including R & D innovation ability, resource allocation ability, R & D path, cost, risk and other factors China is a big producer and exporter of APIs According to data statistics, there are more than 1500 kinds of APIs produced in China and more than 2000 kinds of APIs produced in the world, which shows that China can supply most of the global varieties In addition, the average growth of domestic API market is maintained at more than 8.4%, which is also far higher than the 4% - 5% growth of global API market In terms of export, China's API export scale is close to 30 billion US dollars, which has broad overseas market development space To ensure the stability of the source of APIs is an important way to solve the problem of drug shortage At present, in order to avoid drug shortage caused by rising prices or insufficient production of pharmaceutical raw materials, it is suggested to formulate some guidance policies for the production of pharmaceutical raw materials in shortage so as to ensure the stability of the source of pharmaceutical raw materials in shortage In addition, the industry said that it should continue to strengthen environmental protection and safety supervision, force the transformation and upgrading of API industry, improve the intensive production level of API, and promote enterprises to go on the track of "near zero emission" and green production in the process of adjusting product structure and adopting updated technology At present, under the background of high pressure of environmental protection and rising cost, the shuffling of API industry is accelerated, and many small and backward enterprises have withdrawn from the market It is expected that enterprises with certain environmental protection transformation strength and early production experience are expected to stand firm in the market.
    This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only. This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed description of the concern or complaint, to service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content will be removed immediately.

    Contact Us

    The source of this page with content of products and services is from Internet, which doesn't represent ECHEMI's opinion. If you have any queries, please write to service@echemi.com. It will be replied within 5 days.

    Moreover, if you find any instances of plagiarism from the page, please send email to service@echemi.com with relevant evidence.